Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.40 |
| ▸ | GPR3 | P46089 | 4/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23099878 | 0.89 | PDE2A (0.37) | PDE2AGPR3GRIN2BFFAR4F10 | |
| SCHEMBL10976439 | 0.80 | PDE2A (0.37) | PDE2AGPR3FFAR4F10PTGS1 | |
| SCHEMBL900910 | 0.80 | PDE2A (0.47) | PDE2AGPR3FFAR4ALOX5APFEN1 | |
| SCHEMBL15189277 | 0.78 | FFAR4 (0.42) | GPR3GRIN2BFFAR4PTGS1PTGS2 | |
| SCHEMBL19660216 | 0.77 | FFAR4 (0.36) | PDE2AGPR3FFAR4PTGS1PTGS2 | |
| SCHEMBL17157399 | 0.76 | GPR3 (0.42) | PDE2AGPR3FFAR4ALOX5APFEN1 | |
| SCHEMBL3184782 | 0.76 | GPR3 (0.38) | PDE2AGPR3GRIN2BFFAR4PTGS1 | |
| SCHEMBL28042104 | 0.76 | ALOX5AP (0.39) | PDE2AGPR3HDAC1HDAC6ALOX5AP | |
| SCHEMBL8461879 | 0.76 | GPR3 (0.38) | PDE2AGPR3GRIN2BFFAR4HDAC1 | |
| SCHEMBL21180470 | 0.76 | PDE2A (0.41) | PDE2AGPR3PTGS1PTGS2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10357493-B2 | Metalloenzyme inhibitor compounds | SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) | 2019-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10357493-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | PDE2A 3658/4885GPR3 4762/4885GRIN2B 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.